Nathifa Moyo

Nathifa Moyo

Auto-generated profile, based on publicly available information

Nathifa Moyo

The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
NMNathifa Moyo
Nathifa Moyo
AVAnnette B. Vogel
Annette B. Vogel
SBSøren Buus
Søren Buus
SEStephanie Erbar
Stephanie Erbar
EWEdmund G. Wee
Edmund G. Wee
THTomas Hanke
Tomas Hanke
Focusing T cell responses on the most vulnerable parts of HIV-1, the functionally conserved regions of HIV-1 proteins, is likely a key prerequisite for vaccine success. For a T cell vaccine to efficiently control HIV-1 replication, the vaccine-elicited individual CD8+ T cells and as a population have to display a number of critical traits. If any one of these traits is suboptimal, the vaccine is likely to fail. Fine-tuning of individual protective characteristics of T cells will require iterative stepwise improvements in clinical trials. Although the second-generation tHIVconsvX immunogens direct CD8+ T cells to predominantly protective and conserved epitopes, in the present work, we have used formulated self-amplifying mRNA (saRNA) to deliver tHIVconsvX to the immune system. We demonstrated in BALB/c and outbred mice that regimens employing saRNA vaccines induced broadly specific, plurifunctional CD8+ and CD4+ T cells, which displayed structured memory subpopulations and were maintained at relatively high frequencies over at least 22 weeks post-administration. This is one of the first thorough analyses of mRNA vaccine-elicited T cell responses. The combination of tHIVconsvX immunogens and the highly versatile and easily manufacturable saRNA platform may provide a long-awaited opportunity to define and optimize induction of truly protective CD8+ T cell parameters in human volunteers.

1 January 2018 in Mucosal Immunology
Verified
Journal Article
Open access
KAK M Akram
K M Akram
NMN A Moyo
N A Moyo
GLG H Leeming
G H Leeming
LBL Bingle
L Bingle
SJS Jasim
S Jasim
JSJames P Stewart
James P Stewart
The airway epithelium secretes proteins that function in innate defense against infection. Bactericidal/permeability-increasing fold-containing family member A1 (BPIFA1) is secreted into airways and has a protective role during bacterial infections, but it is not known whether it also has an antiviral role. To determine a role in host defense against influenza A virus (IAV) infection and to find the underlying defense mechanism, we developed transgenic mouse models that are deficient in BPIFA1 and used these, in combination with in vitro three-dimensional mouse tracheal epithelial cell (mTEC) cultures, to investigate its antiviral properties. We show that BPIFA1 has a significant role in mucosal defense against IAV infection. BPIFA1 secretion was highly modulated after IAV infection. Mice deficient in BPIFA1 lost more weight after infection, supported a higher viral load and virus reached the peripheral lung earlier, indicative of a defect in the control of infection. Further analysis using mTEC cultures showed that BPIFA1-deficient cells bound more virus particles, displayed increased nuclear import of IAV ribonucleoprotein complexes, and supported higher levels of viral replication. Our results identify a critical role of BPIFA1 in the initial phase of infection by inhibiting the binding and entry of IAV into airway epithelial cells.

16 June 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAnthony C. Marriott
Anthony C. Marriott
MDMike Dennis
Mike Dennis
JKJennifer A. Kane
Jennifer A. Kane
KGKaren E. Gooch
Karen E. Gooch
GHGraham Hatch
Graham Hatch
MCMiles W. Carroll
Miles W. Carroll
Non-human primates are the animals closest to humans for use in influenza A virus challenge studies, in terms of their phylogenetic relatedness, physiology and immune systems. Previous studies have shown that cynomolgus macaques (Macaca fascicularis) are permissive for infection with H1N1pdm influenza virus. These studies have typically used combined challenge routes, with the majority being intra-tracheal delivery, and high doses of virus (> 107 infectious units). This paper describes the outcome of novel challenge routes (inhaled aerosol, intra-nasal instillation) and low to moderate doses (103 to 106 plaque forming units) of H1N1pdm virus in cynomolgus macaques. Evidence of virus replication and sero-conversion were detected in all four challenge groups, although the disease was sub-clinical. Intra-nasal challenge led to an infection confined to the nasal cavity. A low dose (103 plaque forming units) did not lead to detectable infectious virus shedding, but a 1000-fold higher dose led to virus shedding in all intra-nasal challenged animals. In contrast, aerosol and intra-tracheal challenge routes led to infections throughout the respiratory tract, although shedding from the nasal cavity was less reproducible between animals compared to the high-dose intra-nasal challenge group. Intra-tracheal and aerosol challenges induced a transient lymphopaenia, similar to that observed in influenza-infected humans, and greater virus-specific cellular immune responses in the blood were observed in these groups in comparison to the intra-nasal challenge groups. Activation of lung macrophages and innate immune response genes was detected at days 5 to 7 post-challenge. The kinetics of infection, both virological and immunological, were broadly in line with human influenza A virus infections. These more authentic infection models will be valuable in the determination of anti-influenza efficacy of novel entities against less severe (and thus more common) influenza infections.

28 February 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MRMd Niaz Rahim
Md Niaz Rahim
EWEdmund G Wee
Edmund G Wee
SHShihua He
Shihua He
JAJonathan Audet
Jonathan Audet
KTKevin Tierney
Kevin Tierney
THTomas Hanke
Tomas Hanke
There are a number of vaccine candidates under development against a small number of the most common outbreak filoviruses all employing the virus glycoprotein (GP) as the vaccine immunogen. However, antibodies induced by such GP vaccines are typically autologous and limited to the other members of the same species. In contrast, T-cell vaccines offer a possibility to design a single pan-filovirus vaccine protecting against all known and even likely existing, but as yet unencountered members of the family. Here, we used a cross-filovirus immunogen based on conserved regions of the filovirus nucleoprotein, matrix and polymerase to construct simian adenovirus- and poxvirus MVA-vectored vaccines, and in a proof-of-concept study demonstrated a protection of the BALB/c and C57BL/6J mice against high, lethal challenges with Ebola and Marburg viruses, two distant members of the family, by vaccine-elicited T cells in the absence of GP antibodies. Development of an effective vaccine against filovirus outbreaks is an important public health aim. Here, we demonstrate the principle that cellular responses can not only protect two strains of mice against a high lethal virus challenge of 1000 LD50 in the absence of glycoprotein antibodies, but a single epigraph T–cell vaccine can do so against distant members of the filovirus family, EBOV and MARV. This suggests a possibility that this candidate vaccine also protects against other known as well as yet unencountered viruses of the filovirus family; it is a pan-filovirus vaccine.

5 March 2013 in Immunology
Verified
Journal Article
Open access
PDF file
NMNathifa A. Moyo
Nathifa A. Moyo
EMEmanuele Marchi
Emanuele Marchi
FSFalko Steinbach
Falko Steinbach
Summary: Dendritic cells (DC) are the main immune mediators inducing primary immune responses. DC generated from monocytes (MoDC) are a model system to study the biology of DC in vitro, as they represent inflammatory DC in vivo. Previous studies on the generation of MoDC in horses indicated that there was no distinct difference between immature and mature DC and that the expression profile was distinctly different from humans, where CD206 is expressed on immature MoDC whereas CD83 is expressed on mature MoDC. Here we describe the kinetics of equine MoDC differentiation and activation, analysing both phenotypic and functional characteristics. Blood monocytes were first differentiated with equine granulocyte–macrophage colony‐stimulating factor and interleukin‐4 generating immature DC (iMoDC). These cells were further activated with a cocktail of cytokines including interferon‐γ) but not CD40 ligand to obtain mature DC (mMoDC). To determine the expression of a broad range of markers for which no monoclonal antibodies were available to analyse the protein expression, microarray and quantitative PCR analysis were performed to carry out gene expression analysis. This study demonstrates that equine iMoDC and mMoDC can be distinguished both phenotypically and functionally but the expression pattern of some markers including CD206 and CD83 is dissimilar to the human system.

18 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NMNathifa Moyo
Nathifa Moyo
NBNicola J. Borthwick
Nicola J. Borthwick
EWEdmund G. Wee
Edmund G. Wee
SCSilvia Capucci
Silvia Capucci
ACAlison Crook
Alison Crook
THTomas Hanke
Tomas Hanke
Durability of vaccine-elicited immune responses is one of the key determinants for vaccine success. Our aim is to develop a vaccination strategy against the human immunodeficiency virus type 1 (HIV-1), which induces protective and durable CD8+ T-cell responses. The central theorem of our approach is to focus T cells on highly conserved regions of the HIV-1 proteome and this is achieved through the use of the first-generation conserved vaccine immunogen HIVconsv. This immunogen vectored by plasmid DNA, simian adenovirus and poxvirus MVA was tested in healthy, HIV-1-negative adults in UK and induced high magnitudes of HIVconsv-specific plurifunctional CD8+ T cells capable of in vitro HIV-1 inhibition. Here, we assessed the durability of these responses. Vaccine recipients in trial HIV-CORE 002 were invited to provide a blood sample at 1 and 2 years after vaccination. Their PBMCs were tested in IFN-γ ELISPOT, 25-analyte Luminex, CFSE proliferation and intracellular cytokine staining assays, the last enhanced by HLA-peptide dextramer analysis. 12/12 (1 year) and 8/8 (2 years) returning subjects had median (range) of 990 (150–2495) and 763 (70–1745) IFN-γ SFU/106 PBMC specific for HIVconsv, respectively, and recognized 5 (1–6) out of 6 peptide pools at 2 years. Over one-half of the HIVconsv–specific cells expressed at least 3 functions IFN-γ, TNF-α and CD107a, and were capable of proliferation. Among dextramer-reactive cells, naïve, transitional, effector and terminally differentiated memory subsets were similarly represented. First generation HIVconsv vaccine induced human T cells, which were plurifunctional and persisted for at least 2 years. ClinicalTrials.gov NCT01151319